Announcements Trials
Browse Landscape

Phase

Phase 2 142Phase 1 85Phase 1/2 75Phase 3 17Phase EARLY_PHASE1 5Phase NA 2Phase 2/3 2

Status

Unknown 7Recruiting 4Completed 4Terminated 2Not yet recruiting 2Active not recruiting 2Enrolling by invitation 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Head and Neck Neoplasms 1

Interventions

Radiosurgery 28Magnetic Resonance Spectroscopy 25Blood Specimen Collection 20Radiotherapy 19Surveys and Questionnaires 18Exercise 16Early Intervention, Educational 16Methods 15Cyclophosphamide 15Surgical Procedures, Operative 14Standard of Care 14Radiotherapy, Intensity-Modulated 14Biopsy 13Acupuncture Therapy 12Interviews as Topic 11Cisplatin 11Filgrastim 10Educational Status 10Radiofrequency Ablation 9Magnetic Resonance Imaging 9Fluorodeoxyglucose F18 9fludarabine phosphate 8Radiation 8Gemcitabine 8X-Rays 7Sorafenib 7Practice Guidelines as Topic 7Granulocyte Colony-Stimulating Factor 7Colonoscopy 7Capecitabine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase NA × Terminated × pembrolizumab × Clear all
NCT04801966 2023-05-10

TAILOR

Peter MacCallum Cancer Centre, Australia

Phase NA Terminated
3 enrolled
Tumor-Agnostic

Neoplasms

NCT04453046 2022-12-20

Hemopurifier Plus Pembrolizumab in Head and Neck Cancer

Aethlon Medical Inc.

Phase NA Terminated
2 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡